Почетна › Karcinom plazma ćelija › Тексас
Kliničke studije za Karcinom plazma ćelija u državi Тексас
6 studija za Karcinom plazma ćelija traži učesnike na lokacijama u državi Тексас.
Gradovi u državi Тексас
Zvanični tekst studije (na engleskom)
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas
- Baylor University Medical Center, Dallas
- Houston Methodist Cancer Center Infusion, Houston
- и још 9
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06152575A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
- M D Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT05055063A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas
- Oncology Consultants, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT05651932Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
- Mays Cancer Center at UT Health San Antonio, San Antonio
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT05745285Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
- M D Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст од 18 до 80 · Оба пола · Ажурирано 5. 10. 2026. · NCT06066359Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 17. 9. 2026. · NCT04879043Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.